Modern mucoactive therapy. Clinical aspects of erdosteine use

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Erdosteine is a prodrug, the main indication for use of which is the treatment of acute and chronic lung diseases accompanied by the formation of difficult-to-separate viscous sputum. Today, there is a large evidence base in the literature devoted to the various effects of erdosteine. The presented studies demonstrate the unique properties of erdosteine and confirm that the indication for its use are acute and chronic respiratory diseases with the production of viscous, difficult-to-separate sputum. Additional, but no less important effects of erdosteine, such as antioxidant, anti-inflammatory, antibacterial activity, position it as a drug necessary for the treatment of exacerbations of chronic respiratory diseases. Erdosteine increases the effectiveness of bronchodilators, antibacterial therapy, reduces the frequency and duration of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis, prolongs the time between exacerbations, reduces their risk.

Full Text

Restricted Access

About the authors

Igor V. Leshchenko

Ural State Medical University; Ural Research Institute of Phthisiopulmonology – Branch Campus of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases; Medical Association “New Hospital” LLC

Author for correspondence.
Email: leshchenkoiv@yandex.ru
ORCID iD: 0000-0002-1620-7159
SPIN-code: 1851-8986

Dr. Sci. (Med.), Professor, Department of Phthisiology and Pulmonology, Chief Researcher, Scientific Director of the clinic

Russian Federation, Yekaterinburg; Yekaterinburg; Yekaterinburg

Natalia A. Esaulova

Ural Research Institute of Phthisiopulmonology – Branch Campus of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases

Email: esanat1@yandex.ru
ORCID iD: 0000-0001-9565-3570

Cand. Sci. (Med.), Head of the Department of Differential Diagnostics

Russian Federation, Yekaterinburg

Evgeny A. Medvedsky

Ural State Medical University

Email: leshchenkoiv@yandex.ru

Cand. Sci. (Med.), Associate Professor of the Department of Propaedeutics of Internal Medicine of the Institute of Pediatrics and Reproductive Medicine

Russian Federation, Yekaterinburg

References

  1. Poole P., Black P.N., Cates C.J. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;8:CD001287.118.
  2. Бабак С.Л., Горбунова М.В., Карнаушкина М.А. Многоликий эрдостеин: факты на стол. Consilium Medicum. 2024;26(3):182–6. doi: 10.26442/20751753.2024.3.202740.
  3. Cazzola M., Calzetta L., Page C., et al. Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends Pharmacol Sci. 2019;40(7):452–63. doi: 10.1016/j.tips.2019.04.015.
  4. Cazzola M., Page C., Rogliani P., et al. Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. Drugs. 2020;80(17):1799–809. doi: 10.1007/s40265-020-01412-x.
  5. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2025 Report. Available at: https://goldcopd.org/2025-gold-report1.
  6. Zheng J.P., Kang J., Huang S.Q., et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008;371(9629):2013–18. doi: 10.1016/S0140-6736(08)60869-7.
  7. Zheng J.P., Wen F.Q., Bai C.X., et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet. Respir Med. 2014;2(3):187–94. doi: 10.1016/S2213-2600(13)70286-8.
  8. Zuin R., Palamidese A., Negrin R., et al. High dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Invest. 2005;25(6):401–8. doi: 10.2165/00044011-200525060-00005.
  9. Dal Negro R.W., Visconti M., Micheletto C., Tognella S. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm Pharmacol Ther. 2008;21(2):304–8. doi: 10.1016/j.pupt.2007.07.004.
  10. Park J.S., Park M.-Y., Cho Y.-J., et al. Antiinflammatory effect of erdosteine in lipopolysaccharide-stimulated RAW 264.7 cells. Inflammation. 2016;39(4):1573–1581. Doi: 10.1007/ s10753-016-0393-4.
  11. Jang Y.Y., Song J.H., Shin Y.K., et al. Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide. Pharmacol. 2003;92(4):173–9. Doi: 10.1034/ j.1600-0773.2003.920407.x.
  12. Braga P.C., Dal Sasso M., Sala M.T., Gianelle V. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneimittelforschung. 1999;49(4):344–50. doi: 10.1055/s-0031-1300425.
  13. Dal Negro R.W., Wedzicha J.A., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50(4):1700–11. doi: 10.1183/13993003.00711-2017.
  14. Calverley P.M.A., Papi A., Page C., et al. The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset. Int J Chron Obstruct Pulmon. Dis. 2022;17:1909–20. doi: 10.2147/COPD.S369804.
  15. Moretti M., Bottrighi P., Dallari R., et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res. 2004;30(4):143–52. Available at: https://pubmed.ncbi.nlm.nih.gov/15553660.
  16. Rogliani P., Matera M.G., Page C., et al. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir. Res. 2019;20(1):104. doi: 10.1186/s12931- 019-1078-y.
  17. Министерство здравоохранения Российской Федерации. Хронический бронхит: Клинические рекомендации. Доступно на: https://spulmo.ru 2024. [Ministry of Health of the Russian Federation. Chronic bronchitis: Clinical guidelines. Available at: https://spulmo.ru 2024. (In Russ.)].
  18. Olivieri D., Del Donno M., Casalini A., et al. Activity of erdosteine on mucociliary transport in patients affected by chronic bronchitis. Respir Int Rev Thorac Dis. 1991;58(2):91–4. doi: 10.1159/000195904.
  19. Zanasi A., Menarini A. Erdosteine versus N-acetylcysteine in the treatment of exacerbation of chronic bronchittis. Med Praxis. 1991:12(4):207–17.
  20. Marchioni C.F., Polu J.M., Taytard A., et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int J Clin Pharmacol Ther. 1995;33(11):612–8.
  21. Wenzel R., Fowler A. Acute Bronchitis. Clinical practice. N. Engl. J. Med. 2006;355(20):2125–30. doi: 10.1056/NEJMcp061493.
  22. Woodhead M., Blasi F., Ewig S., et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect. 2011;17(Suppl. 6):E1–59. doi: 10.1111/j.1469-0691.2011.03672.x.
  23. Лещенко И.В., Эсаулова Н.А. Комбинированная терапия продуктивного кашля при острой респираторной вирусной инфекции (ОРВИ) и остром бронхите в реальной клинической практике. Терапевтический архив. 2024;96(1):46–52. [Leshchenko I.V., Esaulova N.A. Combination therapy of productive cough in acute respiratory viral infection (ARVI) and acute bronchitis in real clinical practice. Therapeutic archive. 2024;96(1):46–52. (In Russ.)]. doi: 10.26442/00403660.2024.01.202584.
  24. Smith S.M., Fahey T., Smucny J., Becker L.A. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2017;6(6):CD000245. doi: 10.1002/14651858.CD000245.pub4.
  25. Зайцев А.А., Оковитый С.В., Крюков Е.В. Кашель. Практическое пособие для врачей. М., 2015. [Zaitsev A.A., Okovity S.V., Kryukov E.V. Cough. A practical guide for doctors. Moscow, 2015.
  26. Зайцев А.А., Филон Е.А., Сторожева Ю.И. Острый бронхит – современные возможности мукоактивной терапии. Терапевтический архив. 2023;95(11):943–50. [Zaitsev A.A., Filon E.A., Storozheva Yu.I. Acute bronchitis – modern possibilities of mucoactive therapy. Therapeutic archive. 2023;95(11):943–50. (In Russ.)]. doi: 10.26442/00403660.2023.11.202470.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Рис. 1. Риск госпитализации по поводу обострения ХОБЛ [16] Примечание. * р<0,05.

Download (133KB)
Indexing metadata
3. Fig. 2. Rank graph of drug effectiveness assessment based on their impact on COPD exacerbations

Download (53KB)
Indexing metadata
4. Fig. 3. Effect of erdosteine ​​and NAC on the duration of COPD exacerbation compared with placebo [16]

Download (267KB)
Indexing metadata
5. Fig. 4. Effect of erdosteine ​​on sputum viscosity in comparison with N-acetylcysteine ​​during exacerbation of chronic bronchitis (7-10 day treatment) [19]

Download (61KB)
Indexing metadata
6. Fig. 5. Proportion of patients with no productive cough at visits 2 and 3 (0-1 point on the cough severity scale) [26]

Download (39KB)
Indexing metadata

Copyright (c) 2025 Bionika Media